Oruka Therapeutics, Inc. Common Stock ORKA
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:33:25.391Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:04:54.118100595Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:33:24.902541+00:00
Oruka Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 120.82 | 90.2% | 15.4% | 94.38 | 97.2% | 12.8% |
| 25Δ | 118.00 | 89.5% | 13.3% | 97.34 | 88.6% | 10.4% |
| 30Δ | 115.18 | 87.7% | 11.1% | 100.26 | 77.5% | 7.9% |
| 35Δ | 113.16 | 89.3% | 9.9% | 101.96 | 74.2% | 6.8% |
| 40Δ | 111.19 | 91.0% | 8.7% | 103.66 | 70.9% | 5.6% |
| 45Δ | 109.23 | 90.5% | 7.5% | 105.29 | 68.0% | 4.6% |
| 50Δ | 107.28 | 86.6% | 6.2% | 106.64 | 66.5% | 3.9% |
| 55Δ | 105.33 | 82.8% | 4.9% | 108.00 | 64.9% | 3.3% |
| 60Δ | 103.24 | 88.4% | 4.3% | 109.36 | 63.4% | 2.6% |
| 65Δ | 101.12 | 95.9% | 3.9% | 110.71 | 61.7% | 2.1% |
| 70Δ | 98.73 | 102.0% | 3.4% | 112.05 | 59.8% | 1.7% |
| 75Δ | 96.04 | 106.5% | 2.8% | 113.40 | 57.9% | 1.3% |
| 80Δ | 92.28 | 117.4% | 2.3% | 114.74 | 56.0% | 0.9% |
20Δ
- Pseudo strike
- 120.82
- IV
- 90.2%
- B/E move
- 15.4%
- Pseudo strike
- 94.38
- IV
- 97.2%
- B/E move
- 12.8%
25Δ
- Pseudo strike
- 118.00
- IV
- 89.5%
- B/E move
- 13.3%
- Pseudo strike
- 97.34
- IV
- 88.6%
- B/E move
- 10.4%
30Δ
- Pseudo strike
- 115.18
- IV
- 87.7%
- B/E move
- 11.1%
- Pseudo strike
- 100.26
- IV
- 77.5%
- B/E move
- 7.9%
35Δ
- Pseudo strike
- 113.16
- IV
- 89.3%
- B/E move
- 9.9%
- Pseudo strike
- 101.96
- IV
- 74.2%
- B/E move
- 6.8%
40Δ
- Pseudo strike
- 111.19
- IV
- 91.0%
- B/E move
- 8.7%
- Pseudo strike
- 103.66
- IV
- 70.9%
- B/E move
- 5.6%
45Δ
- Pseudo strike
- 109.23
- IV
- 90.5%
- B/E move
- 7.5%
- Pseudo strike
- 105.29
- IV
- 68.0%
- B/E move
- 4.6%
50Δ
- Pseudo strike
- 107.28
- IV
- 86.6%
- B/E move
- 6.2%
- Pseudo strike
- 106.64
- IV
- 66.5%
- B/E move
- 3.9%
55Δ
- Pseudo strike
- 105.33
- IV
- 82.8%
- B/E move
- 4.9%
- Pseudo strike
- 108.00
- IV
- 64.9%
- B/E move
- 3.3%
60Δ
- Pseudo strike
- 103.24
- IV
- 88.4%
- B/E move
- 4.3%
- Pseudo strike
- 109.36
- IV
- 63.4%
- B/E move
- 2.6%
65Δ
- Pseudo strike
- 101.12
- IV
- 95.9%
- B/E move
- 3.9%
- Pseudo strike
- 110.71
- IV
- 61.7%
- B/E move
- 2.1%
70Δ
- Pseudo strike
- 98.73
- IV
- 102.0%
- B/E move
- 3.4%
- Pseudo strike
- 112.05
- IV
- 59.8%
- B/E move
- 1.7%
75Δ
- Pseudo strike
- 96.04
- IV
- 106.5%
- B/E move
- 2.8%
- Pseudo strike
- 113.40
- IV
- 57.9%
- B/E move
- 1.3%
80Δ
- Pseudo strike
- 92.28
- IV
- 117.4%
- B/E move
- 2.3%
- Pseudo strike
- 114.74
- IV
- 56.0%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 67.45% | |
| 69.12% | |
| 66.42% | |
| 69.11% | |
| 70.23% | |
| 58.82% | |
| 57.78% | |
| 56.56% | |
| 57.11% | |
| 58.21% |
Biotechnology
ORMP
Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or…
More →OTLK
Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company…
More →OVID
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. The company is…
More →PBLS
Parabilis Medicines, Inc. (Ticker: PBLS) is an emerging company at the forefront of the telecommunications sector, dedicated to delivering innovative communication solutions…
More →PBYI
Description unavailable
More →PCVX
Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City,…
More →